Amgen Financial News

biotech giant Amgen on Friday announced its plans to open a new technology and innovation site in Hyderabad, India. The site, to be known as Amgen, will be located in HITEC City, a suburb of Hyderabad, occupying six floors of the RMZ Spire Tower, with a potential to accommodate up to 3,000 people. The site will be operational in Q4 2024. Amgen India will initially build and accelerate new technology solutions and digital capabilities at scale that will enhance efficiencies across the enterprise.

Subscribe to enjoy similar stories. The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds competition to a market currently controlled by Eli Lilly and Novo Nordisk, it also reinforces the dominance of the makers of Wegovy and Zepbound.

Wall Street's three major indexes closed lower on Tuesday as investors booked some profits from a post-election rally and waited anxiously for U.S. inflation data due this week. The indexes had rallied to record highs since the Nov. 5 U.S. election as investors bet on a boost to equities from President-elect Donald Trump's proposed tax cuts and the prospect of easier regulatory policies.

Subscribe to enjoy similar stories. In terms of recent stock-market frenzies, the Ozempic trade nearly tops the list, second only to speculation that artificial intelligence will soon be writing this column. Powerful weight-loss drugs like Wegovy and Zepbound have driven nearly $1 trillion in market-capitalization gains, with most of those gains flowing to Eli Lilly and Novo Nordisk, the dominant players in the obesity-drug market.

Stocks that traded heavily or had substantial price changes on Wednesday: Amgen, Airbnb fall; Fortinet, Dynatrace rise

A top exchange-traded fund provider is betting on the long-term popularity of GLP-1 weight loss drugs.

Stocks that traded heavily or had substantial price changes Friday: Apple, Amgen rise; Expedia, Fortinet fall

portfolio companies as a routine, but amidst the flurry of analysis, have you ever paused to reflect on how much of their inner working we truly grasp? How many acclaimed attributes of greatness remain valid, and how much can we discern from a distance? These questions hold significant implications for the valuations we are prepared to endorse, moulding our long-term returns. Permit me to recount the story of Amgen, a leading biotechnology company based in the United States, as an illustrative case study. A notable book that emphasized the importance of corporate culture by looking at successful companies (stock price performance as a guide) ranked Amgen prominently. Amgen's adeptness in «embracing a myriad of possible dangers» was a strategic manoeuvre that propelled the company to a superior standing.

Amgen (NASDAQ:AMGN) was upgraded to Outperform from Market Perform at BMO Capital on Tuesday, with the price target for the stock raised to $326 from $286 per share.

Explore Wall Street's expert insights with this ProResearch article, which will exclusively be available to InvestingPro subscribers soon. Enhance your investment strategy with ProPicks, our newest product featuring strategies that have outperformed the S&P 500 by up to 700%. This Cyber Monday, enjoy up to 60% off, plus an extra 10% off a 2-year subscription with the code research23 , reserved for the first 500 quick subscribers. To ensure ongoing access to valuable content like this, step up your investment game with InvestingPro.

Obesity rates in the U.S. have been rising steadily for well over a decade and some of the world’s biggest drug developers are tapping into the growing treatment market

By Leroy Leo and Christy Santhosh

Check out the companies making big moves midday.

(Reuters) — Amgen (NASDAQ:AMGN) said on Friday it had completed the $27.8 billion acquisition of Horizon Therapeutics (NASDAQ:HZNP) after it received the go-ahead from the U.S. Federal Trade Commission (FTC) last month on certain conditions.

By Natalie Grover and Martin Coulter

Neumora Therapeutics, which is backed by Amgen and Japan's SoftBank, fell in their market debut on Friday, giving the company a market capitalisation of $2.51 billion. The Watertown, Massachusetts-based company's shares debuted at $16.50 per share on Nasdaq, below the offer price of $17 apiece.

Neumora Therapeutics, which is backed by Amgen and Japan's SoftBank, fell in their market debut on Friday, giving the company a market capitalization of $2.51 billion. The Watertown, Massachusetts-based company's shares debuted at $16.50 per share on Nasdaq, below the offer price of $17 apiece. The ongoing surge in listings points to a nascent recovery in the U.S. IPO market amid growing expectations of a pause in interest rate hikes by the Federal Reserve. Neumora, which is developing drugs for brain diseases, raised $250 million by selling 14.7 million shares priced at the mid-point of its previously disclosed range.

A weak party can get a much stronger opponent to back down, game theory explains, by signaling it is willing to take extreme actions and bear steep costs. But that sort of brinkmanship arguably works only if you don’t have to actually fight—and lose—repeatedly. Federal Trade Commission Chair Lina Khan has been open about her willingness to take on hard cases and lose.

(Reuters) -The U.S. Federal Trade Commission (FTC) has suspended its challenge of Amgen (NASDAQ:AMGN)'s $27.8 billion purchase of Horizon Therapeutics (NASDAQ:HZNP), allowing the FTC to consider whether the agency should settle the case, a filing late on Friday showed.

In this article

In this article